Immune-related gene prognostic index (IRGPI) for lung adenocarcinoma predicts patient prognosis and immunotherapy response.

Zheng Zhu, Wei Feng, Xiao-Yan Tan, Pin-Chao Gu, Wei Song, Hai-Tao Ma

Abstract read

In one paragraph

Article in International journal of clinical and experimental pathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zheng ZhuDepartment of Thoracic Surgery, Suzhou Dushu Lake Hospital (Dushu Lake Hospital Affiliated to Soochow University, Medical Center of Soochow University), Soochow University No. 9 Chongwen Road, Suzhou 215000, Jiangsu, China.

Wei FengDepartment of Thoracic Surgery, Suzhou Dushu Lake Hospital (Dushu Lake Hospital Affiliated to Soochow University, Medical Center of Soochow University), Soochow University No. 9 Chongwen Road, Suzhou 215000, Jiangsu, China.

Xiao-Yan TanDepartment of Thoracic Surgery, Suzhou Dushu Lake Hospital (Dushu Lake Hospital Affiliated to Soochow University, Medical Center of Soochow University), Soochow University No. 9 Chongwen Road, Suzhou 215000, Jiangsu, China.

Pin-Chao GuDepartment of Thoracic Surgery, Suzhou Dushu Lake Hospital (Dushu Lake Hospital Affiliated to Soochow University, Medical Center of Soochow University), Soochow University No. 9 Chongwen Road, Suzhou 215000, Jiangsu, China.

Wei SongEmergency Department, Suzhou Dushu Lake Hospital (Dushu Lake Hospital Affiliated to Soochow University, Medical Center of Soochow University), Soochow University No. 9 Chongwen Road, Suzhou 215000, Jiangsu, China.

Hai-Tao MaDepartment of Thoracic Surgery, Suzhou Dushu Lake Hospital (Dushu Lake Hospital Affiliated to Soochow University, Medical Center of Soochow University), Soochow University No. 9 Chongwen Road, Suzhou 215000, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveWe searched for a predictive biomarker that also predicts whether patients would benefit from immune checkpoint blockade (ICB) treatment from a few angles, because existing biomarkers no longer wholly replicate the interconnections of distinctive elements in the tumor microenvironment (TME).

methodsWe identified 55 pivotal IRGs by performing a WGCNA and univariate Cox regression analysis on a lung adenocarcinoma dataset from the TCGA database. The IRGPI model was then constructed using multivariate Cox regression analysis, which identified 16 genes and verified the use of the GSE68465 database. The AUC of the IRGPI was compared to those of the current biomarkers to determine its predictive potential. Then we examined the molecular and immunological properties of ICB and assessed its effectiveness using CTLA4 expression and TIDE.

resultsPatients with a high IRGPI had a later clinical stage, more severe symptoms, and a worse prognosis. Patients with a low IRGPI had a higher immune escape potential and were less responsive to immunotherapy.

conclusionThe IRGPI may be a biomarker for determining the prognosis of patients and whether they respond favorably to ICB therapy.

Indexed as

immune-related genesimmunotherapyLung adenocarcinomaprognosistumor microenvironment

Identifiers

PMID37970331

PMCPMC10641371

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.